NEW YORK, Jan. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=120441&from=4 CLASS PERIOD: May 10, 2024 to October 1 ...

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humacyte, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and October 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/humacyte-inc-lawsuit-sub ...

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA).Shareholders who purchased shares of HUMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/humacyte-inc-loss-submission-form/?id=118940&from=4 CLASS PERIOD: May 10, 2024 to October ...

NEW YORK, Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Humacyte and certain of its officers an ...

NEW YORK, Dec. 26, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”), of the important January 17, 2025 lead plaintiff deadline. SO WHAT: If you purchased Humacyte securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Humacyte, Inc. (HUMA) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Humacyte, Inc. currently has an average brokerage recomme ...

On Thursday, the FDA granted full approval to Humacyte, Inc.’s HUMA Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and when autologous vein graft is not feasible.Symvess, or the ATEV, is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for arterial replacement and repair.Also Read: Delay Hits Humacyte’s Bioengineered Hum ...

NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Humacyte, Inc. investors who were adversely affected by alleged securities fraud between May 10, 2024 and October 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/humacyte-inc-lawsuit-su ...

– SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – In clinical testing SYMVESS was observed to have high rates of patency, or blood flow, and low rates of amputation and infection – – Highly experienced sales team already recruited and trained in preparation for commercial launch – DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company develo ...

SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte insiders recently offloaded a significant portion of company stock, raising eyebrows amidst a brewing legal storm. According to recent SEC filings, Ayabudge LLC, an entity controlled by Board member Brady W. Dougan, who is married to CEO and President Laura Niklason, disposed of 1.5 million shares over three days in November, netting approximately $6.6 million. The sales, which were treated as indirectly benefiting Dr. Niklason, came as Humacyte navi ...